Mosca M, Bombardieri S
Rheumatology Unit, Department of Internal Medicine, University of Pisa, Pisa, Italy.
Clin Exp Rheumatol. 2006 Nov-Dec;24(6 Suppl 43):S-99-104.
The past few decades have witnessed development and validation of indices to assess activity, damage, and quality of life (QoL) in patients with systemic lupus erythematosus (SLE). These indices are widely used in clinical research and randomised controlled clinical trials, but not in usual clinical care. Definitions of flares and response to therapy have been proposed on the basis of indices. However, criteria for disease remission have not been clearly established for these indices, except for the SLE Disease Activity Index (SLEDAI). Defining remission in SLE in an objective manner depends on reaching agreement on the relative importance of systemic activity, damage, QoL, and laboratory tests, as well as activity and damage of specific organs.
在过去几十年中，已出现并验证了用于评估系统性红斑狼疮（SLE）患者的活动度、损伤及生活质量（QoL）的指标。这些指标在临床研究和随机对照临床试验中广泛应用，但在常规临床护理中却未被采用。基于这些指标，已提出了病情复发及治疗反应的定义。然而，除了SLE疾病活动指数（SLEDAI）外，这些指标的疾病缓解标准尚未明确确立。以客观方式定义SLE的缓解取决于就全身活动度、损伤、生活质量及实验室检查的相对重要性，以及特定器官的活动度和损伤达成共识。
